Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11983306 | 0.86 | TDP1 (0.39) | APP | |
| SCHEMBL11750068 | 0.86 | MAOB (0.55) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL22967380 | 0.85 | MAOB (0.61) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL22967388 | 0.81 | NPC1 (0.41) | — | |
| SCHEMBL20848358 | 0.79 | MAOB (0.67) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL22874653 | 0.79 | MAOB (0.67) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL11751274 | 0.79 | MAOB (0.58) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL23266153 | 0.78 | APP (0.70) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL12423215 | 0.78 | APP (0.70) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL22967750 | 0.77 | MAOB (0.56) | MAOBAPPNR4A2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | WNK1, WNK2, WNK3 | MAOB 975/4885APP 2664/4885NR4A2 2040/4885 |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | WNK1, WNK2, WNK3 | MAOB 975/4885APP 2664/4885NR4A2 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.